Rapid viral expansion and short drug half-life explain the incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 5820-5829

  Schiffer, Joshua T ^a,b   Swan, David A ^b   Corey, Lawrence ^a,b   Wald, Anna ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; 2 AMINOPURINE; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CD8+ T LYMPHOCYTE; CELL DENSITY; CLINICAL EFFECTIVENESS; DISEASE DURATION; DRUG CLEARANCE; DRUG CONCENTRATION; DRUG HALF LIFE; DRUG POTENCY; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; SIMULATION; STOCHASTIC MODEL; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCER; VIRUS REACTIVATION; VIRUS REPLICATION; VIRUS SHEDDING; ANALOGS AND DERIVATIVES; BIOAVAILABILITY; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; DRUG ADMINISTRATION; DRUG EFFECTS; HALF LIFE TIME; HERPES GENITALIS; LYMPHOCYTE COUNT; PHYSIOLOGY; STATISTICAL MODEL; VIROLOGY; VIRUS LOAD;

2-AMINOPURINE; ACYCLOVIR; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; HALF-LIFE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HUMANS; LYMPHOCYTE COUNT; MODELS, STATISTICAL; VIRAL LOAD; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84887501416     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01114-13     Document Type: Article

References (32)

1. Wald A, Corey L, Cone R, Hobson A, Davis G, Zeh J. 1997. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment. J. Clin. Invest. 99:1092-1097.
2. Wald A, Selke S, Warren T, Aoki F, Sacks S, Diaz-Mitoma F, Corey L. 2006. Comparative efficacy of famciclovir and valacyclovir for suppression of recurrent genital herpes and viral shedding. Sex. Transm. Dis. 33:529-533.
3. Schiffer JT, Magaret A, Selke S, Corey L, Wald A. 2011. Detailed analysis of mucosal herpes simplex virus-2 replication kinetics with and without antiviral therapy. J. Antimicrob. Chemother. 66:2593-2600.
4. Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang ML, Schiffer JT, Koelle DM, Corey L, Wald A. 2012. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 379: 641-647.
5. Gupta R, Hill E, McClernon D, Davis G, Selke S, Corey L, Wald A. 2005. Acyclovir sensitivity of sequential herpes simplex virus type 2 isolates from the genital mucosa of immunocompetent women. J. Infect. Dis. 192:1102-1107.
6. Shen L, Rabi SA, Sedaghat AR, Shan L, Lai J, Xing S, Siliciano RF. 2011. A critical subset model provides a conceptual basis for the high antiviral activity of major HIV drugs. Sci. Transl. Med. 3:91ra63. doi:10.1126/ scitranslmed.3002304.
7. Shen L, Rabi SA, Siliciano RF. 2009. A novel method for determining the inhibitory potential of anti-HIV drugs. Trends Pharmacol. Sci. 30:610-616.
8. Schiffer JT, Swan D, Al Sallaq E, Magaret A, Johnston C, Mark KE, Selke S, Ocbamichael N, Kuntz S, Zhu J, Robinson B, Huang ML, Jerome KR, Wald A, Corey L. 2013. Rapid localized spread and immunologic containment define herpes simplex virus-2 reactivation in the human genital tract. Elife 2:e00288. doi:10.7554/eLife.00288.
9. Schiffer JT, Abu-Raddad L, Mark K, Zhu J, Selke S, Magaret A, Wald A, Corey L. 2009. Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci. Transl. Med. 1:1-9.
10. Schiffer JT, Abu-Raddad L, Mark KE, Zhu J, Selke S, Koelle DM, Wald A, Corey L. 2010. Mucosal host immune response predicts the severity and duration of herpes simplex virus-2 genital tract shedding episodes. Proc. Natl. Acad. Sci. U. S. A. 107:18973-18978.
11. Tata S, Johnston C, Huang ML, Selke S, Magaret A, Corey L, Wald A. 2010. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J. Infect. Dis. 201:499-504.
12. Zhu J, Hladik F, Woodward A, Klock A, Peng T, Johnston C, Remington M, Magaret A, Koelle DM, Wald A, Corey L. 2009. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat. Med. 15:886-892.
13. Zhu J, Koelle D, Cao J, Vazquez J, Huang M, Hladik F, Wald A, Corey L. 2007. Virus-specific CD8- T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204:595-603.
14. Wald A, Huang ML, Carrell D, Selke S, Corey L. 2003. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J. Infect. Dis. 188:1345-1351.
15. Novartis Pharmaceuticals. 2011. Famvir (famciclovir) prescribing information. Novartis Pharmaceuticals, East Hanover, NJ.
16. Mark KE, Wald A, Magaret AS, Selke S, Olin L, Huang ML, Corey L. 2008. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J. Infect. Dis. 198:1141-1149.
17. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ. 1977. Selectivity of action of an antiherpetic agent, 9-(2- hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U. S. A. 74:5716-5720.
18. Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P. 1978. 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272:583-585.
19. GlaxoSmithKline. 2007. Zovirax (acyclovir) prescribing information. GlaxoSmithKline, Research Triangle Park, NC.
20. Leary JJ, Wittrock R, Sarisky RT, Weinberg A, Levin MJ. 2002. Susceptibilities of herpes simplex viruses to penciclovir and acyclovir in eight cell lines. Antimicrob. Agents Chemother. 46:762-768.
21. Schiffer J. 2013. Mucosal HSV-2 specific CD8-T-cells represent containment of prior viral shedding rather than a correlate of future protection. Frontiers Immunol. 4:209. doi:10.3389/fimmu.2013.00209.
22. Schiffer JT, Wald A, Selke S, Corey L, Magaret A. 2011. The kinetics of mucosal herpes simplex virus-2 infection in humans: evidence for rapid viral-host interactions. J. Infect. Dis. 204:554-561.
23. Kim JH, Schaenman JM, Ho DY, Brown JM. 2011. Treatment of acyclovir- resistant herpes simplex virus with continuous infusion of highdose acyclovir in hematopoietic cell transplant patients. Biol. Blood Marrow Transplant. 17:259-264.
24. Engel JP, Englund JA, Fletcher CV, Hill EL. 1990. Treatment of resistant herpes simplex virus with continuous-infusion acyclovir. JAMA 263: 1662-1664.
25. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, Rode A, Kinnersley N, Wad P. 2000. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 355:1845-1850.
26. Shin H, Iwasaki A. 2012. A vaccine strategy that protects against genital herpes by establishing local memory T cells. Nature 491:463-467.
27. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. 2009. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. Nat. Immunol. 10:524-530.
28. Posavad C, Koelle D, Shaughnessy M, Corey L. 1997. Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8- cytotoxic T lymphocyte responses. Proc. Natl. Acad. Sci. U. S. A. 94:10289-10294.
29. Posavad CM, Wald A, Kuntz S, Huang ML, Selke S, Krantz E, Corey L. 2004. Frequent reactivation of herpes simplex virus among HIV-1- infected patients treated with highly active antiretroviral therapy. J. Infect. Dis. 190:693-696.
30. Ho D, Neumann A, Perelson A, Chen W, Leonard J, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
31. Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson A, Ho D. 2003. A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J. Virol. 77:5037-5038.
32. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI. 2008. Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 26:4034-4040.